David Currow, BMed, MPH, FRACP, FAChPM, FAHMS of Flinders University, Adelaide, Australia discusses treatment for cachexia. He explains that to date, the only treatment option which has predictably changed the path of cachexia, is treating the underlying disease. None of the drugs under Phase III trials are currently available. In the future, there will be a need to systematically evaluate cachexia in clinical practice to ensure early signs are recognized. In the near future additional therapies are likely to become available. Recorded at the 2016 World Conference of Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC) in Vienna, Austria.